DGAP-News

MOLOGEN AG successfully completes capital increase

DGAP-News: MOLOGEN AG / Key word(s): Capital Increase
MOLOGEN AG successfully completes capital increase

22.04.2015 / 19:54

---------------------------------------------------------------------

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR
INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.

PRESS RELEASE N 05 / 2015 of 04/22/2015

MOLOGEN AG successfully completes capital increase

Berlin, April 22, 2015 - Biotechnology company MOLOGEN AG has placed
5,657,875 new shares with national and international investors. MOLOGEN
AG's share capital has been increased to EUR 22,631,501. Following
registration of the capital increase in the commercial register, the new
shares are scheduled to be admitted for trading on the Frankfurt Stock
Exchange on April 27, 2015. They are expected to be included under the
existing listing ISIN DE0006637200/WKN 663720 on April 28, 2015.

Gross issuing proceeds of EUR 28.3 million provide planning security
The new shares were issued to existing shareholders by way of indirect
subscription rights as well as to qualified investors in the context of an
international private placement at a price of EUR 5.00 per new share.
Existing shareholders exercised indirect subscription rights for 2,788,809
new shares in total. In addition, 454,608 shares were placed among existing
shareholders through oversubscription rights. The remaining shares were
sold by means of an international private placement. As a result of the
capital increase, MOLOGEN receives gross issuing proceeds totaling
approximately EUR 28.3 million. The company has therefore achieved the aim
of the capital increase, which was to ensure planning security at an early
stage for the financing of the next steps in
MOLOGEN's ongoing clinical trials.

Dr. Matthias Schroff, Chief Executive Officer of MOLOGEN AG, explained:
"The successful implementation of this capital increase is testament to the
confidence that existing and new shareholders place in our company. Our
financial resources will enable us to progress to the next important
milestones in the development of our main product candidate, the MGN1703
cancer immunotherapy. The current focus is on completing patient enrolment
for the IMPALA registration study and the phase II IMPULSE trial."

Recruitment of patients for the ongoing phase II trial (IMPULSE) with
MOLOGEN's main product candidate, MGN1703, in the indication of small cell
lung cancer is expected to be completed by the end of this year. The target